Lam Research CapEx increased by 7.5% to $185.12M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 67.4%, from $110.59M to $185.12M. Over 4 years (FY 2021 to FY 2025), CapEx shows an upward trend with a 18.9% CAGR.
An increase often signals growth initiatives and capacity expansion, while a decrease may suggest cost-cutting or a shift toward asset-light strategies.
This metric measures the cash outflows used to acquire, upgrade, and maintain physical assets such as property, building...
Commonly compared as a percentage of revenue; capital-intensive firms like Abbott require consistent investment to remain competitive in medical technology.
capital_expenditures| Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $104.62M | $136.43M | $167.01M | $116.85M | $125.75M | $140.06M | $52.21M | $230.63M | $78.67M | $76.99M | $221.95M | $0.00 | $100.75M | $110.59M | $335.41M | $141.00M | $172.19M | $185.12M |
| QoQ Change | — | +30.4% | +22.4% | -30.0% | +7.6% | +11.4% | -62.7% | +341.8% | -65.9% | -2.1% | +188.3% | -100.0% | — | +9.8% | +203.3% | -58.0% | +22.1% | +7.5% |
| YoY Change | — | — | — | — | +20.2% | +2.7% | -68.7% | +97.4% | -37.4% | -45.0% | +325.1% | -100.0% | +28.1% | +43.6% | +51.1% | — | +70.9% | +67.4% |